Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Interstitial Lung Disease Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

109 recruiting trials for Interstitial Lung Disease. Eligibility criteria explained in plain English.

TrialFinderData lists 109 Interstitial Lung Disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 43% (21 studies); the largest phase groups are Phase 2: 21, Phase 1: 12, Phase 3: 8, Phase 1 / Phase 2: 3.

Research is led by Assistance Publique - Hôpitaux de Paris (4), University of Pennsylvania (2), Bastiaan Driehuys (2), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (drug, 19 trials), followed by Hyperpolarized Xe129, Nintedanib.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
109
Total Trials
109
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Track Interstitial Lung Disease trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06528418

Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model...

Sponsor: ChromX HealthEnrolling: 100001 location
RECRUITINGPhase 3NCT07179380

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension...

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

Sponsor: Insmed IncorporatedEnrolling: 34420 locations
RECRUITINGNCT06476470

Taiwan Interstitial Lung Disease Multi-center Investigation and Registry

The Taiwan Interstitial Lung Disease (ILD) Multi-center Investigation and Registry aims to evaluate the long-term outcomes of patients with fibrotic interstitial lung disease....

Sponsor: Taichung Veterans General HospitalEnrolling: 100001 location
RECRUITINGPhase 1 / Phase 2NCT05746039

Feasibility of Semaglutide in Advanced Lung Disease

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung...

Sponsor: University of PennsylvaniaEnrolling: 81 location
RECRUITINGPhase 2NCT06038630

129Xe MRI Cardiopulmonary

The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.

Sponsor: Bastiaan DriehuysEnrolling: 1251 location
RECRUITINGNCT07254338

Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without...

Fibrosing interstitial lung diseases (FILDs) encompass a group of rare diseases characterized by progressive pulmonary fibrosis leading to respiratory failure. Current treatments...

Sponsor: Hospices Civils de LyonEnrolling: 801 location
RECRUITINGNCT06397677

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators...

Sponsor: University of Colorado, DenverEnrolling: 4504 locations
RECRUITINGNCT05391100

Screening of Patients With Rheumatoid Arthritis for Interstitial Lung Disease

The quantitative and qualitative analysis of RA lung involvement in the Hungarian population

Sponsor: Polyclinic of the Hospitaller Brothers of St. John of God, BudapestEnrolling: 5003 locations
RECRUITINGPhase 3NCT06297096

Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease

The study includes adult patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) to evaluate the efficacy and safety of nintedanib plus tocilizumab combination...

Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, PolandEnrolling: 861 location
RECRUITINGPhase 2NCT05892614

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis...

This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with...

Sponsor: aTyr Pharma, Inc.Enrolling: 2515 locations
RECRUITINGNCT04095351

Connective Tissue Diseases and Lung Manifestations

Despite a number of prospective studies already initiated in the past years, the current epidemiology and course of interstitial lung disease (ILD) and pulmonary hypertension (PH)...

Sponsor: Medical University InnsbruckEnrolling: 1201 location
RECRUITINGNCT03800017

Skeletal Muscle Function in Interstitial Lung Disease

Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that...

Sponsor: University of British ColumbiaEnrolling: 401 location
RECRUITINGPhase 2NCT05785065

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

The goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung...

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)Enrolling: 353 locations
RECRUITINGPhase 2NCT03630211

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published...

Sponsor: Paul SzabolcsEnrolling: 83 locations
RECRUITINGNCT06326957

Reducing Chronic Breathlessness in Adults by Following a Self-guided, Internet Based Supportive Intervention...

Background: Some health conditions make breathing difficult and uncomfortable. When this happens every day, it is called chronic breathlessness. Over 3 million people living with...

Sponsor: King's College Hospital NHS TrustEnrolling: 2461 location
RECRUITINGNCT07512687

Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia

Fibrotic forms of interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are chronic lung disease which often affect how well oxygen can get from the...

Sponsor: State University of New York at BuffaloEnrolling: 241 location
RECRUITINGNCT07541638

Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases

Connective tissue diseases (CTDs) cover a broad range of systemic rheumatic disorders characterized by abnormal immune activation, chronic inflammatory response, and fibrosis of...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 2001 location
RECRUITINGPhase 3NCT05943535

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

Sponsor: United TherapeuticsEnrolling: 69820 locations
RECRUITINGNCT05681962

Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy

The current practice of oxygenation and/or ventilation supports in patients undergoing Fiberoptic Bronchoscopy is very heterogeneous among studies published in the literature; in...

Sponsor: University Magna GraeciaEnrolling: 100001 location
RECRUITINGNCT06855329

PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to...

Sponsor: University of Massachusetts, WorcesterEnrolling: 50013 locations
RECRUITINGNCT05392881

Interstitial Lung Disease Research Unit Biobank

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

Sponsor: University of Kansas Medical CenterEnrolling: 10001 location
RECRUITINGPhase 1NCT04624490

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.

Sponsor: Mario Castro, MD, MPHEnrolling: 2601 location
RECRUITINGNCT07283081

Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias

The investigators hypothesize that in patients with a new diagnosis of Pulmonary Interstitial Disease (PID), adding capillaroscopy to standard care increases the proportion of...

Sponsor: University Hospital, BordeauxEnrolling: 481 location
RECRUITINGNCT06304207

Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease

The goal of this pilot clinical trial is to compare telehealth and onsite supervised maintenance exercise program for adults with Chronic Lung Disease. The specific aims of the...

Sponsor: MGH Institute of Health ProfessionsEnrolling: 301 location
RECRUITINGPhase 1NCT06589219

Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

The purpose of this study is to assess the safety, tolerability and pharmacokinetics single and multiple inhaled doses of CMR316 in healthy volunteers and patients with Idiopathic...

Sponsor: Calibr, a division of Scripps ResearchEnrolling: 1061 location
RECRUITINGPhase 2NCT04925375

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has...

Sponsor: Children's Hospital Medical Center, CincinnatiEnrolling: 386 locations
RECRUITINGPhase 3NCT07201922

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of...

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred,...

Sponsor: Boehringer IngelheimEnrolling: 8020 locations
RECRUITINGPhase 2NCT01280994

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI...

Sponsor: Bastiaan DriehuysEnrolling: 4451 location
RECRUITINGPhase 3NCT04773366

A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol

From January 2010 to December 2014, 150 children with MS-LCH were treated in our hospital following a LCH II (Arm B) based protocol. Treatment was based on a modification of the...

Sponsor: Shanghai Children's Medical CenterEnrolling: 2001 location
RECRUITINGNCT06815185

Rehabilitation Counselling for Patients with Interstitial Lung Disease

Idiopathic pulmonary fibrosis (IPF) is a rare chronic progressive disease of unknown etiology that affects physical and emotional well-being. It is characterized by irreversible...

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaEnrolling: 401 location
RECRUITINGPhase 1NCT05121779

Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT

68Ga-fibroblast activating protein inhibitors(FAPI) has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated...

Sponsor: Peking Union Medical College HospitalEnrolling: 801 location
RECRUITINGPhase 1NCT06712810

Q702 for the Treatment of Patients With Hematologic Malignancies

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called...

Sponsor: Mayo ClinicEnrolling: 462 locations
RECRUITINGPhase 2NCT06189820

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.

Sponsor: Erasme University HospitalEnrolling: 701 location
RECRUITINGPhase 1NCT06821464

A Trial of HRS-9813 in Healthy Subjects

The study is being conducted to evaluate the safety and pharmacokinetics of HRS-9813 after multiple oral administration in healthy subjects.

Sponsor: Guangdong Hengrui Pharmaceutical Co., LtdEnrolling: 601 location
RECRUITINGPhase 2NCT03803787

Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients

This randomized clinical study aims to assess whether prophylactic treatment with inhaled steroids in patients with locally advanced or concomitantly treated non-small cell lung...

Sponsor: Instituto Nacional de Cancerologia de MexicoEnrolling: 722 locations
RECRUITINGNCT06498141

MucinB5 Gene Polymorphism and Leucocytes Telomere Length in Interstitial Lung Diseases

This is an observertional study aimed at Study the association between Mucin B5 rs (35705950) gene polymorphism and Leucocytes telomere length in relation to interstitial lung...

Sponsor: Sohag UniversityEnrolling: 1001 location
RECRUITINGNCT01241305

One-Time DNA Study for Vasculitis

The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of...

Sponsor: University of PennsylvaniaEnrolling: 100014 locations
RECRUITINGPhase 2 / Phase 3NCT05878717

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis...

Sponsor: GlaxoSmithKlineEnrolling: 30020 locations
RECRUITINGPhase 1NCT06992661

A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With...

This Phase 1 clinical trial investigates the pharmacokinetics and safety profile of single-dose inhaled RJ026 in healthy volunteers and patients with interstitial lung disease...

Sponsor: Ruijin HospitalEnrolling: 841 location
RECRUITINGNCT06696027

AYLo - AutoimmunitY and Loss of y

The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims...

Sponsor: University of BonnEnrolling: 5001 location
RECRUITINGNCT06756230

Downhill Walking in IPF

In this study; will examine the effects of downhill walking (eccentric exercise training) on exercise capacity, quality of life, and blood lactate levels in individuals with IPF....

Sponsor: Saglik Bilimleri UniversitesiEnrolling: 341 location
RECRUITINGNCT06001645

Laboratory Biomarkers and Pulmonary Interstitial Emphysema in ARDS (PIE-ARDS)

Barotrauma (pneumothorax, pneumomediastinum) is a well-described complication of Acute Respiratory Distress Syndrome (ARDS), especially in patients with coronavirus disease 2019...

Sponsor: Università Vita-Salute San RaffaeleEnrolling: 1104 locations
RECRUITINGPhase 2NCT06843239

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with...

Sponsor: Zura Bio IncEnrolling: 8020 locations
RECRUITINGPhase 1NCT06817590

Nucleoside Therapy in Patients With Telomere Biology Disorders

The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders. The main...

Sponsor: Suneet AgarwalEnrolling: 361 location
RECRUITINGPhase 2NCT07047690

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week...

Sponsor: Galderma R&DEnrolling: 1623 locations
RECRUITINGNCT05678062

Point-of-care Ultrasound Abnormalities in Eclampsia

Preeclampsia (PE) and eclampsia remain leading causes of maternal morbidity and mortality, in both high-, low-and-middle-income countries. Preeclampsia is a complex, multisystem...

Sponsor: University of Cape TownEnrolling: 701 location
RECRUITINGNCT04807127

A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade

The main goal of this prospective non-interventional exploratory monocentric study is to characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from cancer...

Sponsor: Universitaire Ziekenhuizen KU LeuvenEnrolling: 601 location
RECRUITINGPhase 2NCT04943198

Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of vemurafenib in juvenile patients with histiocytosis...

Sponsor: Anna RaciborskaEnrolling: 251 location
RECRUITINGPhase 1NCT07344558

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The...

Sponsor: Mannkind CorporationEnrolling: 249 locations
RECRUITINGNCT06122233

A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease

The goal of this clinical trial is to compare REBUILD-SM (a purpose-built smartphone app and self-management package) with standard care in people with interstitial lung disease...

Sponsor: University of SydneyEnrolling: 4004 locations

Showing 50 of 109 trials.Search all Interstitial Lung Disease trials

Frequently Asked Questions

There are currently 109 clinical trials for Interstitial Lung Disease, with 109 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Interstitial Lung Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Interstitial Lung Disease, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.